Elite Pharmaceuticals Files 8-K

Ticker: ELTP · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1053369

Elite Pharmaceuticals INC /NV/ 8-K Filing Summary
FieldDetail
CompanyElite Pharmaceuticals INC /NV/ (ELTP)
Form Type8-K
Filed DateJun 16, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-k

TL;DR

Elite Pharma filed a standard 8-K, no major news.

AI Summary

Elite Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Elite Pharmaceuticals is meeting its regulatory reporting obligations. It does not disclose new material information that would immediately impact the company's stock.

Risk Assessment

Risk Level: low — The filing is a routine 8-K and does not contain any new material information, debt, or significant financial events.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing?

This 8-K filing serves as a Current Report for Elite Pharmaceuticals, Inc., covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K filed?

The filing was made on June 16, 2025.

What is Elite Pharmaceuticals' principal executive office address?

The principal executive offices are located at 165 Ludlow Avenue, Northvale, New Jersey 07647.

What is the company's state of incorporation?

Elite Pharmaceuticals, Inc. is incorporated in Nevada.

Does this filing announce any new material events?

The filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but does not specify any new material events beyond standard reporting.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding ELITE PHARMACEUTICALS INC /NV/ (ELTP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing